EQRx
Latest round
- Series B
Last raised
- Nov 2020
Total raised
- $740M
Investors
- 7
About EQRx
Based in Massachusetts, US, and founded in 2019 by Alexis Borisy, Peter Bach, and Sandra Horning, EQRx, Inc. operates as a biotechnology company focused on manufacturing low-cost drugs for treating chronic diseases. In July 2023, Revolution Medicines, Inc. fully acquired EQRx, Inc. for USD 200 million in an all-stock deal. EQRx, Inc. manufactures drugs for the treatment of life-threatening and chronic diseases such as cancers, including lung, breast, and other solid tumors through the re-engineering process. Following the merger, the firm plans to use the proceeds to continue building its clinical development organization, accelerate the business toward commercialization of its late-stage drug candidates, and continue to amass a robust pipeline of innovative medicines to address areas of burden.
Who invested in EQRx
7 investors across 2 rounds
See all investors in EQRx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about EQRx
Who invested in EQRx?
EQRx has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has EQRx raised?
EQRx has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did EQRx last raise money?
EQRx's most recent round on record is a Series B, in Nov 2020.
What does EQRx do?
Based in Massachusetts, US, and founded in 2019 by Alexis Borisy, Peter Bach, and Sandra Horning, EQRx, Inc.
Where is EQRx headquartered?
EQRx is headquartered in Cambridge, US.
Which VCs invest in companies like EQRx?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at EQRx's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like EQRx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.